)
Oculis (OCS) investor relations material
Oculis Stifel 2026 Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Privosegtor clinical results and development
Phase II ACUITY showed 18-letter LCVA improvement at month 3, retinal ganglion cell preservation, reduced neurofilament and GFAP, and good safety; received FDA Breakthrough Therapy and EMA PRIME designations, and is now in Phase III.
PIONEER-1 is an event-driven optic neuritis trial; the first patient was dosed in late August, U.S. screening and randomization are underway, and enrollment is starting in Europe.
Plan is to activate 60 sites, with half targeted by year-end 2026; randomization is expected to finish in 2027, with topline potentially around year-end 2027, subject to refinement after 50% enrollment.
PIONEER-1 primary endpoint is LCVA; key secondary endpoints include GCIPL and neurofilament, with GFAP exploratory. Treatment is 5 days, readout at month 3, and 100 patients will be followed to month 12 for the FDA safety database.
Development strategy prioritizes inflammatory indications—optic neuritis and acute MS relapse—before ischemic NAION; NAION remains a hypothesis requiring human validation in a planned Phase II/III study.
Licaminlimab and dry-eye strategy
Licaminlimab targets TNFR1-positive dry-eye patients; RELIEF showed 5x greater signs improvement and 7x greater symptoms improvement in this subgroup, and FDA agreed to TNFR1-enriched Phase III testing.
PREDICT-1 is a symptom trial with mean improvement in TNFR1-positive patients as the primary endpoint, all-comers as a secondary endpoint, and responder improvement of more than 20 points also assessed; two-thirds of patients are expected to be TNFR1-positive.
Base-case program is two signs and two symptoms trials, planned for 650 patients; after PREDICT-1, the team plans to meet FDA, which could require only one additional signs trial.
TNFR1 testing uses a rapid, noninvasive saliva-swab qPCR; the intended strategy is test-and-treat for an estimated 1.5 million moderate-to-severe TNFR1-positive patients.
PREDICT-1 results are expected in December 2026 or January 2027.
Pipeline plans and financial position
At the December 8, 2026 R&D Day, management plans to update PIONEER-1 execution and provide protocol detail for PIONEER-2 and PIONEER-3; an IND for PIONEER-3 was expected in Q4 2026.
PIONEER-1 includes optic neuritis broadly, excluding AQP4/NMO from the mITT; management expects roughly two-thirds MS and one-third non-MS patients. PIONEER-2 focuses on optic neuritis in MS patients.
Privosegtor is administered by IV infusion; an oral formulation is the most advanced alternative being developed, while drop and intravitreal formulations remain early-stage.
Cash was CHF 252 million, expected to fund operations through H2 2029, including PIONEER-1, PIONEER-2, PIONEER-3 and PREDICT-1; this excludes the BlackRock loan facility.
- PREDICT-1 readout nears as privosegtor advances across neuroprotection indications.OCS
3rd Annual Guggenheim Healthcare Innovation Conference - Late-stage trials advance as $252.0M in cash supports runway into 2H 2029.OCS
Q3 2026 - ACUITY signals support a registrational optic neuritis program for privosegtor.OCS
Euretina Innovation Spotlight (EIS) 2026 Presentation - TNFR1-guided dry-eye development targets greater benefit in biomarker-positive patients.OCS
Study presentation - Phase III programs in dry eye and optic neuritis advance, with MS and NAION expansion planned.OCS
2026 Global Healthcare Conference - Precision medicine and targeted trials drive clinical and commercial strategy, with strong funding.OCS
H.C. Wainwright 28th Annual Global Investment Conference - Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth.OCS
Q2 2026 - Late-stage neuro-ophthalmic and ophthalmic programs advance toward pivotal milestones with strong financial backing.OCS
Corporate presentation - Positive clinical results and precision medicine advances set the stage for major milestones in 2024–2025.OCS
H.C. Wainwright 26th Annual Global Investment Conference
)
)
)
)
)
)
)
)